Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q2 2026
Kiniksa Pharmaceuticals International (KNSA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 28, 2026
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $244M for the second quarter 2026 (Q2 2026), +55% from a year earlier and +14% from the quarter before. Operating margin was 11.2%, net earnings $25.4M (10.4% of revenue).
Kiniksa Pharmaceuticals International, Q2 2026: revenue $244M (+55% year over year), operating margin 11.2%, net earnings $25.4M, operating cash flow $47.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $244M | +14% | +55% |
| Operating profit | $27.2M | -7% | +35% |
| Net earnings | $25.4M | +13% | +43% |
| Operating cash flow | $47.2M | -6% | +68% |
| Free cash flow | $46.5M | -7% | +67% |
What changed
Revenue was $243.6M in Q2 2026, up 55% year over year and up 14% from the previous quarter.
Operating profit was $27.2M, a 11.2% margin (down 1.7 points year over year). Of the extra revenue versus Q2 2025, 8% reached operating profit, below the 13% margin then. Total costs grew 58% against revenue growth of 55%. The fastest-growing cost line was Research & development (+118%). Net earnings were $25.4M, up 43% year over year. The effective tax rate was 18.3%.
Operating cash flow was $47.2M (up 68% year over year), 186% of net earnings. Non-cash charges added back $472K of depreciation and amortization and $11.6M of share-based compensation. Working capital and other items added $9.7M. Capital expenditures of $663K left free cash flow of $46.5M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the second quarter 2026?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $244M for the second quarter 2026 (Q2 2026), +55% from a year earlier and +14% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the second quarter 2026?
Operating profit was $27.2M (11.2% of revenue) and net earnings $25.4M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.